KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Tax Provisions (2023 - 2024)

Aquestive Therapeutics has reported Tax Provisions over the past 2 years, most recently at -$14000.0 for Q4 2024.

  • Quarterly results put Tax Provisions at -$14000.0 for Q4 2024, down 113.86% from a year ago — trailing twelve months through Mar 2025 was -$14000.0 (down 105.71% YoY), and the annual figure for FY2024 was -$14000.0, down 105.71%.
  • Tax Provisions for Q4 2024 was -$14000.0 at Aquestive Therapeutics, down from $101000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for AQST hit a ceiling of $284000.0 in Q2 2023 and a floor of -$140000.0 in Q3 2023.